Kazia Therapeutics Ltd. (KZIA), Wednesday announced data from a Phase I study evaluating the use of concurrent Paxalisib and radiation therapy for the treatment of patients with solid tumor brain metastases or leptomeningeal metastases harboring PI3K pathway mutations.
The data revealed that over the two-third of participants, the maximum tolerated dose achieved intracranial response, and 67 percent partial response rate was reported in patients treated with 45 mg Paxalisib and radiotherapy.
Kazia said the treatment was well-tolerated at a maximum dose of 45 mg per day in advanced solid tumor patients with brain metastases and PI3K pathway mutations.
Based on the data, John Friend, chief executive officer of the biotechnology company, suggested that the combination therapy appeared to be a viable treatment approach for addressing the tumor radioresistance in patients harboring PI3K pathway mutations.
Currently, Kazia's stock is climbing 11.37 percent, to $0.48 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.